Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry

BACKGROUND: About 50% of all primary breast cancers show a low-level expression of HER2 (HER2-low), defined as immunohistochemically 1+ or 2+ and lack of HER2 gene amplification measured by in situ hybridization. This low HER2 expression is a promising new target for antibody–drug conjugates (ADCs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Gampenrieder, Simon Peter, Rinnerthaler, Gabriel, Tinchon, Christoph, Petzer, Andreas, Balic, Marija, Heibl, Sonja, Schmitt, Clemens, Zabernigg, August Felix, Egle, Daniel, Sandholzer, Margit, Singer, Christian Fridolin, Roitner, Florian, Hager, Christopher, Andel, Johannes, Hubalek, Michael, Knauer, Michael, Greil, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670265/
https://www.ncbi.nlm.nih.gov/pubmed/34906198
http://dx.doi.org/10.1186/s13058-021-01492-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670265/
https://www.ncbi.nlm.nih.gov/pubmed/34906198
http://dx.doi.org/10.1186/s13058-021-01492-x

Ejemplares similares